R-01 is under clinical development by Hangzhou Neoantigen Therapeutics and currently in Phase I for Gastrointestinal Tract Cancer. According to GlobalData, Phase I drugs for Gastrointestinal Tract Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how R-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

R-01 overview

iNeo-Vac-R01 is under development for the treatment of advanced metastatic digestive system neoplasms, cholangiocarcinoma, pancreatic cancer, hepatocellular carcinoma, gastric cancer, colorectal carcinoma and lung cancer. The vaccine candidate comprises of mRNA vaccine encoding neoantigens and is administered as an injection through intrahepatic route.

For a complete picture of R-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.